CUTX-101 is under clinical development by Cyprium Therapeutics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CUTX-101’s likelihood of approval (LoA) and phase transition for Menkes Disease (Kinky Hair Disease) took place on 17 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CUTX-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CUTX-101 overview

CUTX-101 (Copper histidinate) is under development for the treatment of Menkes disease. The drug candidate is administered through subcutaneous route. Copper histidine acts as a replacement therapy.

Quick View CUTX-101 LOA Data

Report Segments
  • Innovator
Drug Name
  • CUTX-101
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Genetic Disorders
Key Developers
  • Sponsor Company: Cyprium Therapeutics
  • Originator: Eunice Kennedy Shriver National Institute of Child Health and Human Development
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.